Promising Long-Term Data for Vamorolone in Duchenne Muscular Dystrophy Presented at MDA Conference
Orlando, Florida – New data presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 indicate that AGAMREE® (vamorolone) maintains long-term effectiveness comparable to traditional corticosteroids in treating Duchenne muscular dystrophy (DMD), while demonstrating a significantly improved safety profile. The findings, announced March 9, 2026, by Santhera Pharmaceuticals (SIX: SANN), are based on analyses of up to eight years of patient exposure, including data from the ongoing GUARDIAN study. This offers renewed hope for individuals and families navigating the challenges of this debilitating genetic condition.
Duchenne muscular dystrophy is a progressive genetic disorder primarily affecting males, characterized by muscle weakness and degeneration. Traditional treatments often involve corticosteroids like prednisone and deflazacort, which, while effective in slowing disease progression, are associated with significant long-term side effects, including growth suppression, vertebral fractures and cataracts. The search for therapies that balance efficacy with improved tolerability has been a critical focus for researchers and clinicians.
Vamorolone Demonstrates Comparable Efficacy with Reduced Side Effects
The data presented at the MDA conference included a comprehensive analysis of real-world comparative data, comparing AGAMREE® to both prednisone and deflazacort. Researchers found that vamorolone demonstrated comparable long-term effectiveness in maintaining ambulation – the ability to walk – with a statistically non-significant difference compared to prednisone (p=0.8587) and deflazacort (p=0.6544). This suggests that patients treated with vamorolone experience a similar rate of disease progression in terms of mobility as those on standard corticosteroid regimens.
However, the key differentiator appears to be safety. The analyses revealed a striking reduction in vertebral fractures among patients treated with AGAMREE®, with only 8.1% experiencing fractures compared to 41.9% in those treated with deflazacort (p=0.0082). Patients on vamorolone maintained normal height, exhibiting a mean height advantage of 12.17 cm compared to patients on classic corticosteroids, where significant growth stunting is commonly observed (p<0.0001). The incidence of cataracts was also significantly lower in the vamorolone group, affecting 5.3% of patients compared to 37.8% on deflazacort (p=0.015), and notably, no glaucoma was observed in patients receiving vamorolone.
GUARDIAN Study and Long-Term Follow-Up
The findings are based on data from the ongoing, open-label, multicenter GUARDIAN study (NCT06713135), as well as data from participants in earlier clinical studies who continued treatment through various access programs. The dataset encompasses up to eight years of AGAMREE® exposure, with a median follow-up of approximately five years. The study design involved a propensity-matched historical control cohort treated with deflazacort or prednisone, allowing for a robust comparison of outcomes.
Santhera Pharmaceuticals reported positive topline results from a five-year analysis of AGAMREE® data in November 2025, foreshadowing the more comprehensive findings presented at the MDA conference. These earlier results indicated an improved safety profile alongside comparable effectiveness to standard of care corticosteroids, highlighting the potential of vamorolone as a valuable treatment option.
Implications for DMD Treatment
The long-term data presented at the MDA conference reinforce the potential of vamorolone to address a critical unmet necessitate in the treatment of Duchenne muscular dystrophy. The ability to maintain efficacy while significantly reducing the burden of steroid-associated side effects could lead to improved long-term outcomes for patients, allowing them to maintain mobility, growth, and overall quality of life. The reduction in vertebral fractures and cataracts, in particular, represents a substantial benefit, as these complications can significantly impact a patient’s well-being.
“These data demonstrate that vamorolone maintains long-term effectiveness comparable to traditional corticosteroids, while improving tolerability and meaningfully reducing key steroid-associated side effects that often lead to dose reductions or discontinuations that impact long-term patient outcomes,” stated Santhera Pharmaceuticals in a press release. The company, headquartered in Pratteln, Switzerland, is traded on the SIX Swiss Exchange under the ticker symbol SANN.
Understanding Vamorolone’s Mechanism of Action
Vamorolone is a novel dissociative glucocorticoid receptor modulator. Unlike traditional corticosteroids, which activate the glucocorticoid receptor in all tissues, vamorolone selectively dissociates from the receptor in non-muscle tissues, potentially minimizing systemic side effects while maintaining anti-inflammatory benefits in muscle tissue. This targeted approach is believed to be responsible for the improved safety profile observed in clinical trials and long-term follow-up studies.
Future Directions and Access
The GUARDIAN study remains ongoing, and Santhera Pharmaceuticals continues to collect and analyze data to further refine our understanding of vamorolone’s long-term effects. The company is also working to expand access to AGAMREE® for patients with DMD through various access programs. The availability of this innovative therapy represents a significant step forward in the fight against Duchenne muscular dystrophy, offering hope for a brighter future for those affected by this challenging condition.
The MDA Clinical & Scientific Conference, held in Orlando, Florida, is a leading international forum for researchers, clinicians, and families affected by neuromuscular diseases. The presentation of these data at this prestigious conference underscores the importance of vamorolone as a potential new standard of care for DMD.
Key Takeaways:
- AGAMREE® (vamorolone) shows comparable long-term effectiveness to prednisone and deflazacort in maintaining ambulation in DMD patients.
- Vamorolone is associated with significantly fewer vertebral fractures compared to deflazacort.
- Patients treated with vamorolone maintain normal height, avoiding the growth suppression often seen with traditional corticosteroids.
- The incidence of cataracts is substantially lower with vamorolone compared to deflazacort.
The ongoing GUARDIAN study will continue to provide valuable insights into the long-term benefits and risks of vamorolone. For the latest updates on AGAMREE® and Duchenne muscular dystrophy, please consult with your healthcare provider or visit the Santhera Pharmaceuticals website. We encourage readers to share their thoughts and experiences in the comments below.